NCT02690337View on ClinicalTrials.gov

Study of DS-1123a in Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Advanced Solid Malignant Tumors
Interventions
DRUG

DS-1123

starting intravenous (IV) dose of 0.1 mg/kg.

Trial Locations (1)

277-8577

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT02690337 - Study of DS-1123a in Advanced Solid Tumours | Biotech Hunter | Biotech Hunter